
|Videos|October 14, 2022
Efficacy and Quality of Life Data from 5-Year Follow-Up of CheckMate 214
Author(s)Rana R. McKay, MD
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
First Patients Dosed With TLX597-Tx in Trial for mHSPC
4
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
5































